Spherix Media
Across the pharma lifecycle, an accurate and complete market view is essential to stay ahead of the curve and uncover emerging healthcare trends.
Breadth of physician-driven research underscores emerging trends in oncology as three abstracts are accepted at ASCO 2026: EXTON, PA, April 29, 2026 — Spherix Global Insights continues to expand its presence in oncology market intelligence with the release of new findings from its RealTime Dynamix™ service focused on PD-1 inhibition
High adoption rates for obesity treatment are noted across both LillyDirect and NovoCare platforms, but key workflow differences drive a split in preferences EXTON, PA, April 24, 2026 — As the obesity treatment landscape evolves, new access channels are reshaping how patients receive care. Since the launch of Eli Lilly’s
On World Hemophilia Day 2026, Spherix Global Insights announces the publication of data revealing early but evolving uptake across novel agents, with growing demand for deeper patient-level insights as treatment pathways diversify EXTON, PA — April 17, 2026 — New data from Spherix Global Insights’ Launch Dynamix™ service indicate that
2026 patient audit data from Spherix Global Insights reveals biologic use nearing 60% of patients, increasing competitive switching, and a deep pipeline poised to further expand targeted treatment options. EXTON, PA — April 13, 2026 — The systemic lupus erythematosus (SLE) market continues to evolve toward biologic-driven care, with increasing
With physicians identifying up to one-third of patients as candidates, early adoption reflects strong enthusiasm tempered by cautious real-world uptake. Exton, PA – March 31, 2026 – Spherix Global Insights today announced new findings from Launch Dynamix™: Aqvesme in Thalassemia, highlighting early physician perceptions and adoption dynamics of Agios’ Aqvesme
Originally published in BioNews Report says most doctors see therapies becoming standard 1st-line treatment Most doctors who treat multiple myeloma expect that CAR T-cell therapies will soon became the standard first-line treatment, according to new research from market analytics company Spherix Global Insights. The trend marks a shift in attitudes among myeloma experts. Last year,
Findings from Spherix Global Insights’ research reveal nearly three-quarters anticipate frontline use, with significant near-term share gains expected in second-line disease Exton, PA – March 19, 2026 — Spherix Global Insights’ Q1 2026 update of RealTime Dynamix™: Multiple Myeloma findings point to a clear inflection in treatment strategy, as physicians
Saphnelo Surpasses Benlysta in CLE as Physicians Expand Use of Biologics Ahead of Key 2027 Catalysts
Spherix Global Insights finds rising biologic adoption across specialties, with most physicians signaling intent to adopt CLE-specific pipeline therapies earlier in treatment. EXTON, PA — March 17, 2026 – As treatment strategies evolve in cutaneous lupus erythematosus (CLE), physicians are increasingly turning to advanced systemic therapies while evaluating emerging targeted
New report using real-world data cites care hurdles, need for multiple meds In the U.S., having sickle cell disease (SCD) continues to place a heavy clinical burden on patients, who often require multiple medications, frequent blood transfusions, and the use of opioids to control pain. Most individuals with SCD report high barriers
New data from Spherix Global Insights show most physicians view patients as gene therapy candidates, yet few have initiated the treatment regime Exton, PA – March 10, 2026 – Spherix Global Insights today announced the release of its 2026 Patient Chart Dynamix™: Sickle Cell Disease (US) report, an in-depth analysis of 133 real-world patient charts collected from 86
The decision is made off findings from the 2 phase 3, randomized, double-blind, placebo-controlled POETYK PsA-1 and POETYK PsA-2 trials. he FDA approveddeucravacitinib (Sotyktu; Bristol Myers Squibb) for the treatment of adults with active psoriatic arthritis (PsA), the company announced March 7, 2026.¹ The decision makes deucravacitinib the first oral TYK2 inhibitor
A patient audit of more than 1,000 lupus nephritis charts highlights growing experience with biologics and calcineurin inhibitors, alongside rising off-label adoption of SGLT2 inhibitors. EXTON, PA — March 06, 2026 – New findings from Spherix Global Insights’ Patient Chart Dynamix™: Lupus Nephritis (US), 2025 report reveal a treatment landscape
Recently released data finds 22% of patients are not optimally managed despite growing use of Novartis’ Fabhalta, Alexion’s Voydeya, and Roche’s PiaSky Exton, PA., March 5, 2026 — Spherix Global Insights today announces the release of its latest Market Dynamix™: Paroxysmal Nocturnal Hemoglobinuria (PNH) (US) 2026 study, revealing a sizable
EXTON, PA, March 3, 2026 — Spherix Global Insights today announced the launch of a new suite of services focused on Market Access, expanding the company’s advisory capabilities to provide biopharma manufacturers and other stakeholders with comprehensive, data-driven insights across payer strategy, key account dynamics, organized customer engagement, and patient services
After UCB’s Bimzelx scored five approvals in just two years, the Belgian drugmaker has quickly made a blockbuster out of its up-and-coming immunology powerhouse. As the first med to selectively inhibit IL-17F as well as IL-17A, Bimzelx entered the crowded plaque psoriasis arena in 2023 before tacking on indications the
Findings show strong pre-launch awareness, safety-driven TYK2 differentiation from JAK inhibitors, and opportunity for Bristol Myers Squibb to strengthen rheumatology standing. EXTON, PA — February 27, 2026 — With the FDA’s March 6, 2026 PDUFA date approaching for Sotyktu (deucravacitinib) in psoriatic arthritis (PsA), new findings from RealTime Dynamix™: Psoriatic Arthritis Q1 (US), show that U.S. rheumatologists are actively monitoring the
